We observed a strikingly analogous trend in “The Human Protein Atlas” dataset wherein all the PC patients with higher Orai3 protein expression in the PC tumors succumbed by 5.5 years whereas more than 20% of patients with low Orai3 levels in the PC tumors survived for more than 7.5 years (Figure 1C). This evidence concerns the gene ORAI3 and pachyonychia congenita.